Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation. - Epstein-Peterson ZD; Drill E; Aypar U; Batlevi CL; Caron P; Dogan A; Drullinsky P; Gerecitano J; Hamlin PA; Ho C; Jacob A; Joseph A; et al. (Haematologica, 2024)